What High Inflation Could Say About Our Future

The Pulse Beneath the Prices

Inflation isn’t just an economic number — it’s a cultural weather report. When prices rise faster than paycheques, the public mood shifts, politics polarise, and power structures quietly realign.

The headlines focus on grocery bills, interest rates, and fuel costs, but insiders in banking, real estate, and geopolitics know inflation is less about this month’s CPI report and more about the invisible forces that decide who wins and who loses over the next decade.

The Hidden Players Behind “Market Forces”

Central banks will say they’re “managing” inflation, but a deeper look suggests select groups benefit more from prolonged inflationary cycles than the public realises.
For example, one well-connected European banker — who hasn’t been photographed in public since 2019 — reportedly told a private conference that inflation “reshuffles the deck” in their favour, allowing asset-heavy families and institutions to expand holdings while cash-strapped households downsize.

It’s not just conspiracy theory. Historical data shows that inflationary periods are prime hunting grounds for:

Private equity firms scooping up distressed real estate.
Multinational corporations locking in long-term supply contracts at today’s prices, anticipating future scarcity.
Political incumbents framing inflation as an external crisis to consolidate legislative power.

Signals from the Past

Every major inflationary period in modern history — from the oil shocks of the 1970s to the post-2008 commodity surges — carried a political aftermath.

In the 1970s, inflation accelerated the decline of manufacturing cities and the rise of finance capitals.
In the late 2000s, inflation after the financial crisis reshaped housing markets, permanently pricing out entire demographics from homeownership.

The gossip from inside a Washington think tank suggests that some policymakers are quietly preparing for a similar “generation divide” — where younger citizens will accept renting as a permanent reality, while wealth consolidates in older, asset-owning hands.

How Inflation Shapes the Future Economy

Permanent Price Floors – Once certain prices go up (like housing), they rarely come back down. Expect a “new normal” rather than a return to pre-inflation affordability.
Supply Chain Realignment – Inflation exposes fragile supply routes; businesses that vertically integrate now will control markets later.
Investment Power Shift – Hard assets like land, art, and rare materials will be hoarded by those who can afford to wait out market instability.

Cultural Ripples

Inflation doesn’t just affect wallets — it changes behavior.
Luxury dining in some capitals is still booming, but not because everyone can afford it. In one Middle Eastern city, high-end restaurants are packed nightly because the wealthy are “parking” cash in experiences, avoiding currencies they suspect will lose value.

Meanwhile, mid-tier brands are quietly disappearing, squeezed between discount giants and elite luxury. “The middle,” as one fashion insider put it over an espresso in Milan, “is no longer a safe place to do business.”

The Dangerous Comfort of Short Memories

What’s striking is how quickly societies forget inflation once it stabilises. By then, the long-term shifts are locked in — ownership patterns, wage hierarchies, and political alignments have already changed.
An economist I met in Zurich likened it to “a chess game where half the moves are made in the dark.” By the time the lights come back on, you realise your king is trapped.

Why These Matter

Understanding inflation isn’t about predicting next quarter’s rates — it’s about recognising the structural rewiring of the economy while it’s still in progress.

If inflation becomes the “new normal,” it will:

Cement generational wealth divides.
Accelerate the monopolisation of key industries.
Redefine what it means to be middle class — potentially making it more of an aspiration than a reality.

For those willing to look past the headlines, high inflation is not just a problem to survive, but a signal about who will hold influence in the next economic order. And ignoring that signal could mean waking up in a world where your ability to shape your own financial destiny has quietly evaporated.

‍

The City Must Learn to Live With Water

The modern city has spent more than a century attempting to make water disappear. Rain falls onto roofs, roads and pavements. Gutters collect it. Drains capture it. Pipes bury it. Pumps move it. Rivers are channelled. Wetlands are filled. Coastlines are defended. The engineering objective has largely been straightforward: separate water from urban life as efficiently as possible. That model is reaching its limits. Around 600 million urban residents already live with significant annual flood hazard, according to the World Bank. Globally, 1.81 billion people live in flood-prone areas, while annual urban flood losses could approach $50 billion by 2050. Rapid urbanisation, ageing drainage infrastructure, land subsidence and changing rainfall patterns are interacting with the basic physical reality that cities have covered enormous portions of naturally absorbent ground with concrete and asphalt. Yet the consequential story is not simply that cities need bigger drains. A different philosophy of urban resilience is emerging: parks designed to flood temporarily; streets shaped to carry cloudbursts; wetlands restored as infrastructure; plazas capable of storing stormwater; permeable landscapes that absorb rainfall; buildings elevated or adapted to tolerate inundation; sensors that reveal water movement in real time; and neighbourhoods organised around the understanding that some water cannot — and perhaps should not — be engineered away. The World Bank increasingly describes effective urban flood management as an integration of grey infrastructure, green infrastructure, nature-based systems, planning, warning systems and institutional reform, rather than reliance on any single engineering intervention. The conceptual reversal is enormous. For generations, successful urbanisation meant controlling nature sufficiently to construct the city. The next generation of urbanism may require something more intelligent: designing the city so nature can still function inside it.

The Price of Money Is Becoming Political Again

For much of the post-financial-crisis era, wealthy economies became accustomed to an extraordinary condition: money was cheap. Governments could borrow heavily, companies could finance expansion at modest rates, asset prices could rise on abundant liquidity, and households learned to treat low-cost mortgages as something approaching economic normality. That world is disappearing fast. Across major economies, long-term government borrowing costs have climbed towards levels not seen for years or decades. On 17 August, the US 30-year Treasury yield reached roughly 5.31 per cent, its highest level since 2007. Japan’s 10-year government bond yield subsequently approached 2.95 per cent, a three-decade high, while German borrowing costs have risen to 15-year highs. The OECD describes the present combination of elevated financing requirements and elevated yields as exceptional compared with the previous two decades. Behind those numbers is a larger structural contest. Governments need capital for debt refinancing, defence, infrastructure, pensions, healthcare and climate resilience. Technology companies require extraordinary sums for artificial-intelligence infrastructure. Energy systems require grids, generation and storage. Businesses require investment. Families require mortgages and credit. These demands do not occupy separate universes. They ultimately encounter the same fundamental economic resource: capital. And when many powerful institutions want more of it simultaneously, the price of money stops being an obscure financial-market variable. It becomes a question of who gets financed, at what price, and at whose expense.

Cancer Vaccines Are Becoming Personal

For more than a century, the word vaccine has largely meant prevention: teach the immune system to recognise a threat before disease takes hold. Cancer is forcing medicine to reconsider that architecture. A new generation of experimental therapies is attempting something considerably more individual: sequence a patient’s tumour, identify mutations particular to that cancer, manufacture instructions corresponding to selected tumour-specific targets, and teach the patient’s immune system to recognise what belongs to the cancer growing inside that particular body. On 19 August, Moderna and Merck announced that their Phase III trial of the investigational personalised mRNA therapy intismeran autogene, used with Merck’s checkpoint inhibitor Keytruda after surgery for high-risk melanoma, achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. The global trial enrolled 1,137 patients with resected stage IIB–IV melanoma. No new safety concerns were identified in the announcement. Full detailed Phase III results remain pending. The result matters because this is not simply another medicine administered to everyone carrying the same diagnosis. Intismeran is designed individually. Tumour and normal tissue are sequenced; mutations are analysed computationally; selected neoantigens — abnormal molecular features produced by the tumour — become the targets encoded into an mRNA therapy manufactured for that patient. Earlier Phase IIb evidence provides important context rather than a substitute for the unreleased Phase III detail. At five-year median follow-up, Moderna and Merck reported that intismeran plus Keytruda reduced the risk of recurrence or death by 49 per cent and distant metastasis or death by 59 per cent compared with Keytruda alone in that smaller study. The larger significance therefore extends beyond melanoma. Medicine has spent generations classifying disease so that patients with sufficiently similar conditions can receive sufficiently similar treatments. Personalised cancer vaccines suggest a different possibility: the diagnosis may identify the disease, while the tumour itself helps design the medicine. If that model succeeds across cancers, one of medicine’s great industrial achievements — standardisation — will begin coexisting with its apparent opposite: manufacturing treatment for one.